{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:27:17Z","timestamp":1773012437834,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202106070028"],"award-info":[{"award-number":["202106070028"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Evaluation Clinical Practice"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Real\u2010world long\u2010term adherence and drug patterns are essential in hyperlipidemia management. However, the evidence was unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims and Objectives<\/jats:title>\n                    <jats:p>This study aimed to assess long\u2010term adherence, drug usage patterns of anti\u2010hyperlipidemic monotherapy, associated risk factors, and develop risk prediction models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective inception cohort study utilising data from the University of Groningen's IADB.nl dispensing database. The study included new users of anti\u2010hyperlipidemic monotherapies\u2014simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin, and fibrates, with approximately a follow\u2010up to 10 years. Using logistic regression, we developed risk prediction models for adherence and drug utilisation patterns, including discontinuation, continuation, switching, and add\u2010on therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Simvastatin users demonstrated high prevalence of high adherence throughout the study (83.6%\u201390.2%) and had the highest continuation rate (39.2%) with minimal switching or add\u2010on therapy use. Individuals aged 40 and older exhibited better adherence and higher continuation rates. Male patients had lower adherence but higher continuation rates. High adherence was associated with both high continuation and increased switching or add\u2010on therapy use. Patients using diabetes medications had better adherence, higher continuation, and lower switching and add\u2010on rates, whereas those on antiparkinson drugs had lower continuation rates. Recent initiators showed better continuation and lower switching or add\u2010on rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Simvastatin users demonstrated higher adherence and continuation rates compared to other anti\u2010hyperlipidemic monotherapy users. Factors including older age, female sex, and diabetes medications use were associated with improved adherence. Sensitivity analyses using equivalent dosing regimens yielded consistent findings. These insights into adherence and drug patterns are critical for informing personalised strategies to optimise cardiovascular disease prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jep.70380","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:02:22Z","timestamp":1771480942000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010Term Adherence and Drug Utilisation Patterns Among New Users of Anti\u2010Hyperlipidemic Monotherapy: Development of a Risk Prediction Model"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2175-8307","authenticated-orcid":false,"given":"Xuechun","family":"Li","sequence":"first","affiliation":[{"name":"Unit PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy University of Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-7210","authenticated-orcid":false,"given":"Eelko","family":"Hak","sequence":"additional","affiliation":[{"name":"Unit PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy University of Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-7564","authenticated-orcid":false,"given":"Jens H. J.","family":"Bos","sequence":"additional","affiliation":[{"name":"Unit PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy University of Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-2608","authenticated-orcid":false,"given":"Catharina C. M.","family":"Schuiling\u2010Veninga","sequence":"additional","affiliation":[{"name":"Unit PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy University of Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6041-1061","authenticated-orcid":false,"given":"Sumaira","family":"Mubarik","sequence":"additional","affiliation":[{"name":"Unit PharmacoTherapy, \u2010Epidemiology and \u2010Economics, Groningen Research Institute of Pharmacy University of Groningen Groningen the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573403x16999201210200342"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00916-3"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"e_1_2_14_5_1","volume-title":"AHRQ Comparative Effectiveness Reviews. Combination Therapy Versus Intensification of Statin Monotherapy: An Update","author":"Monroe A. K.","year":"2014"},{"issue":"9","key":"e_1_2_14_6_1","first-page":"139","article-title":"Epidemiology and Management of Hyperlipidemia","volume":"23","author":"Karr S.","year":"2017","journal-title":"The American Journal of Managed Care"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0420-5"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201196"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S245365"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"e_1_2_14_11_1","volume-title":"Endotext","author":"Feingold K. R.","year":"2000"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.S479120"},{"key":"e_1_2_14_13_1","volume-title":"Praktische Handleiding bij de NHG\u2010Standaard CVRM (2019)","author":"Genootschap N. H.","year":"2019"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01290"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1034251"},{"key":"e_1_2_14_16_1","volume-title":"Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial for the R TWANG Package","author":"Ridgeway G. M. D.","year":"2022"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6587165"},{"key":"e_1_2_14_18_1","volume-title":"Endotext","author":"Feingold K. R.","year":"2000"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018792702"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2011.09.004"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0b013e31816b43d3"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01208-9"},{"key":"e_1_2_14_23_1","unstructured":"Healthcare HHSaSJs. Medication Information Fibrates accessed September 10 2012 https:\/\/www.stjoes.ca\/patients-visitors\/patient-education\/f-j\/DrugCardBookletFibratePORTRAIT-pe%20."},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-016-0619-9"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.S47518"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)09327-3"},{"key":"e_1_2_14_27_1","unstructured":"Drug Interactions Between Carbidopa\/Levodopa and Rosuvastatin https:\/\/www.drugs.com\/drug-interactions\/carbidopa-levodopa-with-rosuvastatin-515-0-2031-0.html."},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.111.000071"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007480"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.022"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01115-w"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71120-z"}],"container-title":["Journal of Evaluation in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jep.70380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jep.70380","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jep.70380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:11:22Z","timestamp":1773007882000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jep.70380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/jep.70380"],"URL":"https:\/\/doi.org\/10.1111\/jep.70380","archive":["Portico"],"relation":{},"ISSN":["1356-1294","1365-2753"],"issn-type":[{"value":"1356-1294","type":"print"},{"value":"1365-2753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70380"}}